Venus Remedies, a leading research based global pharmaceutical company, has received patent from Australian Patent office (APO), Government of Australia, for Vancoplus, a novel antibiotic formulation to combat methicillin resistant staphylococcus aureus (MRSA) infections.

After Potentox, this is company’s second patent grant from the APO and is valid till February 2026.

Elated on this achievement, Dr Manu Chaudhary, joint managing director and director research, Venus Remedies Limited says, “As Antimicrobial Resistance is a growing concern globally, getting this patent grant from Australia for our Antimicrobial Resistance product “Vancoplus is like a milestone in the war against microbial resistance.” Vancoplus, which is not only a cost effective product but also reduces treatment time, is the only known remedy to control MRSA, VRSA (vancomycin resistance staphylococcus aureus) and multi-drug resistant bacteria which causes meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin infections and staphylococcal endocarditis.

As per the reports of Medicines Australia, already 7000 Australians die each year from drug-resistant bacteria, such as Golden Staph (staphylococcus aureus) infections. According to the Australasian Society for Infectious Diseases, Antibiotic resistance is one of the foremost issues that will affect health care worldwide, including Australia, in the coming decades.

Adding further to the achievement Dr Chaudhary said, “Keeping the present scenario into consideration, our revolutionary product 'Vancoplus' can prove to be a life saving solution to curb and eradicate the deadly infections from its roots in Australia and across the globe. We are all geared up to achieve more milestones in treating microbial resistance.” Vancoplus has the potential to restrict transfer of bacterial resistance from MRSA to other strains by preventing conjugation and transfer of plasmids containing resistant genes. “Vancoplus” is also the only known therapeutic option for breaking of bacterial biofilm formed by gram positive bacteria, one of the most common causes of bacterial resistance.

The total market size of MRSA in the world accounts for $9 billion. At present it is growing at CAGR of 4.8 per cent which is estimated to reach to $12.4 billion by 2017. Venus expects to grab a fair share of this market within 3 years of launch of its novel research product Vancoplus in all major territories of the world.

Vancoplus, a strategically designed formulation through CVMC technology, is the landmark achievement of Venus Medicine Research Centre team. The formulation is the most effective and safe option available in the market to curb the notorious MRSA strain and multi-drug resistant microbes primarily responsible for causing various infections and staphylococcal endocarditis. In addition to its effectiveness in curbing infections, Vancoplus therapy also significantly reduces treatment time and cost and can be considered as empiric therapy to curb menace of MRSA.

The product Vancoplus has already received patent grants from countries such as USA, Japan, South Africa, New Zealand and Ukraine. Patent grants from Canada, Europe, Brazil, Mexico and India are awaited. It has already been successfully launched in several markets worldwide and is under registration in many countries.